IDH1 and acute myeloid leukemia: The introduction of IDH inhibitors and their promising results from clinical studies along with understanding the mechanisms of resistance to these inhibitors and the exploration of potential agents for overcoming resistance is another example of how target therapy has found its way into management of AML patients for better clinical outcomes.